Lucinda Crabtree Appointed CFO of Oxford Biomedica
Oxford Biomedica plc (LSE: OXB), a prominent player in the field of cell and gene therapy manufacturing, is excited to announce the appointment of Lucinda Crabtree, Ph.D., as its new Chief Financial Officer (CFO) and board member. With her extensive experience in finance and investment, particularly within the pharmaceutical industry, she is set to play a crucial role in the company's future growth.
Lucinda Crabtree's Professional Journey
Prior to her role at Oxford Biomedica, Lucinda Crabtree held the position of CFO at MorphoSys AG, where she skillfully led a financial team across various regions, including the US and Germany. Her career in finance encompasses significant leadership roles at Autolus Therapeutics, a company listed on Nasdaq. This background showcases her ability to navigate the complexities of finance, particularly in the biopharmaceutical sector.
A Solid Foundation in Financial Leadership
Crabtree’s expertise is further enhanced by her experience in investment and banking. She has held key positions at esteemed institutions such as Woodford Investment Management, Goldman Sachs, and Jefferies. This diverse experience has provided her with a unique perspective on financial management and market dynamics.
Dr. Frank Mathias on Crabtree's New Role
Dr. Frank Mathias, the Chief Executive Officer of Oxford Biomedica, expressed his enthusiasm about Crabtree's appointment. He remarked, "We are thrilled that Lucy has joined Oxford Biomedica as our new CFO and Board member. Lucy brings a wealth of experience from her roles as a CFO and her time as a healthcare investor and equity research analyst. Her expertise will be invaluable as we expand our international presence as a leading cell and gene therapy CDMO.”
Lucinda's Aspirations for Oxford Biomedica
Lucinda Crabtree has shared her excitement about this new opportunity, stating, “I am thrilled to be joining Oxford Biomedica as CFO. I believe strongly in the Company’s growth strategy and look forward to collaborating with the Board and the leadership team. Together, I am confident we will achieve our mission of enabling our expanding client base to deliver life-changing therapies to patients.”
The Mission of Oxford Biomedica
Oxford Biomedica is dedicated to providing innovative therapies that significantly benefit patients. Recognized for its groundbreaking work in cell and gene therapy, the company has established a strong reputation as a contract development and manufacturing organization (CDMO) focused on quality and innovation.
About Oxford Biomedica
With more than 25 years of expertise in viral vectors, Oxford Biomedica collaborates with leading pharmaceutical and biotechnology companies around the globe. They specialize in critical areas such as viral vector development and manufacturing, concentrating on technologies like lentivirus and adeno-associated virus (AAV).
Innovative Technologies and Capabilities
Oxford Biomedica's capabilities span from initial development to full commercialization, backed by robust quality-assurance systems and extensive regulatory knowledge. The team provides a variety of unique technologies tailored for viral vector manufacturing, including advanced production systems and innovative cell lines.
Contact Information
For inquiries, please reach out to:
Oxford Biomedica plc:
Sophia Bolhassan, Head of Investor Relations – T: +44 (0) 1865 509 737 / E: ir@oxb.com
ICR Consilium:
T: +44 (0)20 3709 5700 / E: oxfordbiomedica@icrhealthcare.com
Mary-Jane Elliott / Angela Gray / Davide Salvi
Frequently Asked Questions
Who is Lucinda Crabtree?
Lucinda Crabtree is the newly appointed Chief Financial Officer of Oxford Biomedica, bringing extensive experience from her previous roles in the pharmaceutical sector.
What is the role of the Chief Financial Officer?
The CFO oversees the financial operations of the company, strategizing and managing financial risks while aligning with the company's growth objectives.
Why did Lucinda join Oxford Biomedica?
Lucinda joined to leverage her finance experience within a company dedicated to developing life-changing therapeutic solutions for patients.
What is Oxford Biomedica's mission?
Oxford Biomedica aims to facilitate the delivery of innovative cell and gene therapies to patients globally.
What technologies does Oxford Biomedica use?
They utilize a range of technologies for viral vector manufacturing, emphasizing advanced systems for optimal production and quality assurance.
